Monographs: Dosage forms: Specific monographs: Norethisterone tablets (Norethisteroni compressi)

Category. Progestational steroid.

Storage. Norethisterone tablets should be kept in a well-closed container, protected from light.

Additional information. Strength on the 6th invitation to manufacturers of reproductive health products to submit an expression of interest (EOI) for product evaluation to the WHO Prequalification Team - Medicines: 0.35 mg. Additional strengths available 0.625 and 5 mg.

Requirements

Comply with the monograph on Tablets.

Definition. Norethisterone tablets contain not less than 90.0% and not more than 110.0% of the amount of Norethisterone (C20H26O2) stated on the label.

Identity tests

Either test A or test B may be applied.

A. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the conditions given under “Assay”, method A. The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to the retention time of the peak due to norethisterone in the chromatogram obtained with solution (2).

B. Carry out the test as described under 1.14.1 Chromatography, Thin-layer chromatography using silica gel R1 as the coating substance and a mixture of 95 volumes of dichloromethane R and 5 volumes of methanol R as the mobile phase. Apply separately to the plate 10 µL of each of the following 3 solutions in dehydrated ethanol R. For solution (A) dissolve a quantity of the powdered tablets, equivalent to about 2 mg of norethisterone, in 10 mL, centrifuge for 10 minutes and use the supernatant liquid. For solution (B) use a solution containing 0.2 mg of norethisterone RS per mL. For solution (C) use a solution containing 0.2 mg of norethisterone RS and 2 mg ethinylestradiol RS per mL. Develop the plate. After removing the plate from the chromatographic chamber allow it to dry in air or in a current of air and spray with sulfuric acid/ethanol (10%) TS. Heat the plate to 105 °C for 10 minutes, allow to cool and examine the chromatogram in ultraviolet light (365 nm). The principal spot in the chromatogram obtained with solution (A) corresponds in position, appearance and intensity with that obtained with solution (B). The test is not valid unless the chromatogram obtained with solution (C) shows two clearly separated spots.

Dissolution

For 0.625 mg tablets. Carry out the test as described under 5.5 Dissolution test for solid oral dosage forms using as the dissolution medium 900 mL of a solution of 0.09% sodium lauril sulfate R in hydrochloric acid (~3.65 g/L) TS and rotating the paddle at 75 revolutions per minute. At 45 minutes withdraw a sample of 10 mL of the medium through an in-line filter and use the filtrate as solution (1). For solution (2) dissolve a suitable amount of norethisterone RS in 10 mL of ethanol (~750 g/L) TS and dilute to a suitable volume with dissolution medium to obtain a solution containing 0.7 µg per mL.

Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the chromatographic conditions as described under “Assay” but injecting alternately 50 µL each of the solutions (1) and (2).

For each of the six tablets calculate the total amount of norethisterone (C20H26O2), in the medium, using the declared content of (C20H26O2) in norethisterone RS. The amount of norethisterone in solution for each tablet is not less than 80% (Q) of the amount declared on the label.

For 0.35 mg tablets . Carry out the test as described above for 0.65 mg tablets but using 500 mL of a solution of 0.09% sodium laurilsulfate R in hydrochloric acid (~3.65 g/L) TS as the dissolution medium.

Related substances

Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using a stainless steel column (15 cm x 4.6 mm) packed with end-capped particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (5 µm).

Use the following conditions for gradient elution:

mobile phase A: water R;

mobile phase B: acetonitrile R.

Time
(min)

Mobile phase A
(% v/v)

Mobile phase B
(% v/v)

Comments

0–20

63

37

Isocratic

20–25

63 to 20

37 to 80

Linear gradient

25–35

20

80

Isocratic

35–36

20 to 63

80 to37

Return to initial composition

36–45

63

37

Re-equilibration

Operate with a flow rate of 1.0 mL per minute. As a detector use a variable wavelength spectrophotometer set at a wavelength of 254 nm and, for impurity C, D and I at 210 nm.

Prepare the following solutions using as the diluent a mixture of 40 volumes of water R and 60 volumes of acetonitrile R. For solution (1) transfer a quantity of the powdered tablets, containing the equivalent of about 10 mg of norethisterone, in 10 mL and sonicate for 15 minutes. Stir vigorously for 15 minutes, centrifuge and use the supernatant. For solution (2) dilute a suitable volume of solution (1) to obtain a solution containing 1.0 µg of norethisterone per mL. For solution (3) dissolve 5.0 mg of norethisterone for system suitability RS (containing the impurities A, B, C, D, E, F, G and H) in the solvent and dilute to 2.0 mL. For solution (4) use a solution containing about 2.5 µg of ethinylestradiol RS (impurity I) per mL.

Inject solution 20 µL of solution (3). The assay is not valid unless in the chromatogram recorded at the wavelength of 254 nm the peaks due to impurity B (with a relative retention of about 0.9) and due to norethisterone (retention time about 10 minutes) are baseline separated and the peak-to-valley ratio (Hp/Hv) is at least 1.2, where Hp is the height above the baseline of the peak due to impurity A (with a relative retention of about 0.8) and Hv is the height above the baseline of the lowest point of the curve separating this peak from the peak due to impurity B.

Inject alternately 50 µL each of solution (1), (2) and (4).

Use the chromatogram obtained with solution (3) and the chromatogram supplied with norethisterone for system suitability RS to identify the peaks due to the impurities A, B, C, D, E, F, G and H. The impurities are eluted at the following relative retention with reference to norethisterone (retention time about 10 minutes): impurity H about 0.3; impurity A about 0.8; impurity B about 0.9; impurity I about 1.1 (at 210 nm); impurity G about 1.5; impurity C about 1.6 (at 210 nm); impurity D about 1.7 (at 210 nm); impurity E about 2.3 and impurity F about 2.4. Use the chromatogram obtained with solution (4) to identify the peak due to impurity I.

In the chromatogram obtained with solution (1):

  • the area of any peak corresponding to impurity A, when multiplied by a correction factor of 2.5, is not greater than 5 times the area of the principal peak obtained with solution (2) (0.5 %);
  • the area of any peak corresponding to impurity F, when multiplied by a correction factor of 1.4, is not greater than 5 times the area of the principal peak obtained with solution (2) (0.5%);
  • the area of any peak corresponding to impurity H, when multiplied by a correction factor of 1.7, is not greater than 5 times the area of the principal peak obtained with solution (2) (0.5%);
  • the area of any peak corresponding to impurity I, recorded at 210 nm, when multiplied by a correction factor of 0.2, is not greater than 5 times the area of the principal peak obtained with solution (2) (0.5%);
  • the area of any other peak, other than the principal peak due to norethisterone, is not greater than 5 times the area of the principal peak obtained with solution (2) (0.5%);

Assay

Either method A or B may be applied.

A. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using a stainless steel column (25 cm x 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl group (5µm) . As the mobile phase use a mixture of 65 volumes of methanol R and 35 volumes of water R.

Prepare the following solutions using the mobile phase as the diluent. Weigh and powder 20 tablets. For solution (1) transfer a quantity of the powdered tablets, containing about 1.25 mg of norethisterone, accurately weighed, to a 50 mL volumetric flask, add 30 mL mobile phase and sonicate for 15 minutes. Cool to room temperature, dilute to volume and mix. Centrifuge the suspension and use the supernatant. For solution (2) use a solution containing 25 µg of norethisterone RS per mL. For solution (3) use a solution containing 25 µg of norethisterone RS and 25 µg of ethinylestradiol RS per mL.

Operate with a flow rate of 1.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 254 nm.

Inject alternately 20 µL each of the solutions (1), (2) and (3). Record the chromatograms for about 20 minutes. The resolution between norethisterone and ethinylestradiol in the chromatogram from solution (3) should be not less than 4.0.

Measure the areas of the peak responses obtained in the chromatograms of solutions (1) and (2) and calculate the percentage content of norethisterone (C 20H26O2) in the tablets, using the declared content of C20H26O2 in norethisterone RS.

B. Use the average of the 10 individual results obtained in the test for “Uniformity of content”.

Uniformity of content

The tablets comply with the test for 5.1 Uniformity of content for single-dose preparations using the following method of analysis.

Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the chromatographic conditions as described under “Assay”, method A.

Prepare the following solutions using the mobile phase as diluent. For solution (1) transfer one tablet to a 25 mL volumetric flask. Add about 15 mL of the diluent, sonicate to disintegrate and shake for 10 minutes and dilute to volume. Centrifuge the suspension and use the clear supernatant liquid. For solution (2) use a solution containing 25 µg of norethisterone RS per mL (for 0.625 mg tablets ) or 14 µg of norethisterone RS per mL (for 0.35 mg tablets).

Inject alternately 20 µL each of solution (1) and (2). Measure the areas of the peaks corresponding to norethisterone obtained in the chromatograms and calculate the content of norethisterone (C20H26O2) in each tablet, using the declared content of C20H 26O2 in norethisterone RS.

Impurities

The impurities limited by the requirements of this monograph include those listed in the monograph on Norethisterone.

to previous sectionto next section